Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 37 (RPL23AP37) represents a processed pseudogene in the human genome that is homologous to the ribosomal protein L23a gene (RPL23A). Unlike the functional RPL23A gene, which encodes a component of the 60S ribosomal subunit crucial for protein synthesis[5][7], RPL23AP37 does not encode a functional protein and is not expressed as part of any characterized biological pathway or disease mechanism. The existence of multiple processed pseudogenes for ribosomal proteins is common, resulting from ancestral gene duplication and retrotransposition events[5][7]. RPL23AP37 has no established physiological role, is not linked to drug interactions or clinical biomarkers, and is not considered a molecular target for pharmacological intervention[3][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 37 (RPL23AP37).